Roche: share up as 2024 guidance raised
(CercleFinance.com) - On Thursday Roche raised its guidance for FY 2024, after noting an acceleration in sales growth in Q2.
The Swiss biopharmaceutical company said that Q2 sales rose 9% at constant exchange rates, with the decline in sales of Covid-19-related products now a lesser drag on business.
H1 sales rose 5%, underpinned by strong demand for its drugs and diagnostic tools.
Core operating income rose by 11% to almost 11.3bn Swiss francs, with EPS up 9%.
For 2024, Roche now anticipates around 5% annual sales growth at constant exchange rates, while core EPS is expected to grow at less than 10%.
Following this publication, Roche shares rose by 2.8% on Thursday morning in Zurich, posting the second highest increase in the SMI index behind Lonza.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The Swiss biopharmaceutical company said that Q2 sales rose 9% at constant exchange rates, with the decline in sales of Covid-19-related products now a lesser drag on business.
H1 sales rose 5%, underpinned by strong demand for its drugs and diagnostic tools.
Core operating income rose by 11% to almost 11.3bn Swiss francs, with EPS up 9%.
For 2024, Roche now anticipates around 5% annual sales growth at constant exchange rates, while core EPS is expected to grow at less than 10%.
Following this publication, Roche shares rose by 2.8% on Thursday morning in Zurich, posting the second highest increase in the SMI index behind Lonza.
Copyright (c) 2024 CercleFinance.com. All rights reserved.